Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Operating margin-139.8%-120pp-4.2%+21.8pp-8.9%+22.4pp-13.3%+27.7pp-20.1%+28.3pp
Net margin-140.2%-120pp-4.5%+21.6pp-8.8%+23.7pp-13.6%+27.6pp-20.4%+50.4pp
EBITDA margin-135.4%-122pp0.4%+19.4pp-3.7%+20.0pp-7.7%+25.9pp-13.8%+27.9pp
Free cash flow margin-30.3%10.5%
Returns
Return on equity-335.8%-303pp-8.6%+28.4pp-15.8%+24.0pp-24.2%+46.8pp-33.1%+51.3pp
Return on assets-101%-89.5pp-3.1%+10.3pp-5.7%+9.4pp-8.4%+11.3pp-11.5%+20.7pp
Efficiency
Asset turnover0.7×+0.2×0.7×+0.2×0.6×+0.2×0.6×+0.1×0.6×+0.1×
Liquidity
Current ratio2.1×-1.1×2.7×-0.4×3.3×0.0×3.1×-0.1×3.2×-0.5×
Quick ratio-1.1×2.6×-0.4×3.2×0.0×-0.1×-0.4×
Cash ratio-0.5×1.2×-0.4×1.4×-0.3×1.3×-0.6×1.4×-1.2×
Leverage
Debt-to-equity0.1×0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Interest coverage-55.3×-49.9×-1.5×+4.6×-2.9×+3.8×-4×+3.6×-5.3×+2.2×
Per Share
Book value per share$4.12-13.6%$6.27+32.0%$5.12+5.5%$5.13+5.8%$4.77-4.6%
Valuation
Market capitalization$5.57B+152%$4.08B+106%$3.68B+99.9%$2.53B+57.8%$2.21B+88.1%
Enterprise value$5.33B+162%$3.84B+114%$3.46B+109%$2.35B+67.5%$2.03B+128%
Price / sales9.8×+4.0×7.8×+1.9×7.8×+1.8×5.9×-0.2×5.8×+0.6×
Price / book23×+13.5×13×+4.2×12.6×+4.7×9.9×+2.9×9.5×+4.5×
EV / sales9.4×+4.0×7.4×+2.0×7.3×+1.9×5.5×+0.2×5.4×+1.4×
Free cash flow yield-3.1%1.3%
Earnings yield-14.3%-10.8pp-0.6%+3.9pp-1.1%+4.3pp-2.3%+4.5pp-3.5%+10.0pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Mirum Pharmaceuticals, Inc.'s ratios come from?
Every ratio is computed from Mirum Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.